Roquefort Therapeutics PLC Director/PDMR Shareholding (9862Y)

TIDMROQ

RNS Number : 9862Y

Roquefort Therapeutics PLC

19 January 2022

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Director/PDMR Shareholding

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, advises that Stephen West, Executive Chairman has purchased ordinary shares in the Company in the market, as detailed below:

 
                Number of Ordinary     Average Price   Total Consideration 
   Name                     Shares    Paid Per Share                  Paid 
 Stephen West              150,000       10.36 pence          GBP15,542.10 
               -------------------  ----------------  --------------------

Following the above purchase of shares, Mr West holds interests in the following Company securities:

 
                 Number of Ordinary   % of Issued Share   Number of Warrants 
   Name                 Shares Held             Capital                 Held 
 Stephen West             4,550,000              6.33 %            7,500,000 
                -------------------  ------------------  -------------------

4,399,000 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.

Enquiries:

 
 Roquefort Therapeutics plc 
                                          +44 (0)20 3290 
 Stephen West (Chairman)                            9339 
 Buchanan (Public Relations) 
  Ben Romney / Jamie Hooper / George 
  Beale 
                                          +44 (0)20 7466 
  Optiva Securities Limited (Broker)                5000 
                                          +44 (0)20 3411 
 Christian Dennis                                   1881

For further information on Roquefort Therapeutics, please visit www.roquefortinvest.com and @RoquefortTherap on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, Lyramid Pty Ltd ("LYRAMID"), is a pre-clinical biotech company focused on developing first in class Midkine inhibiting RNA therapeutics drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within mRNA therapeutics has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.

Through extensive research resulting in validation through publication in over 1,000 scientific journals, Lyramid has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. Lyramid holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). LYRAMID's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.

This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK MAR, provides further detail:

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                           Stephen West 
      -----------------------------  ---------------------------------------- 
 2     Reason for the notification 
      ----------------------------------------------------------------------- 
 a)    Position/status                Executive Chairman 
      -----------------------------  ---------------------------------------- 
 b)    Initial notification           Initial 
        /Amendment 
      -----------------------------  ---------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------- 
 a)    Name                           Roquefort Therapeutics plc 
      -----------------------------  ---------------------------------------- 
 b)    LEI                            254900P4SISIWOR9RH34 
      -----------------------------  ---------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ----------------------------------------------------------------------- 
 a)    Description of the             Ordinary shares of GBP0.01 par value 
        financial instrument, 
        type of instrument             ISIN: GB00BMDQ2T15 
        Identification code 
      -----------------------------  ---------------------------------------- 
 b)    Nature of the transaction      Purchase of 150,000 ordinary shares 
      -----------------------------  ---------------------------------------- 
 c)    Price(s) and volume(s)         Price(s)                      Volume(s) 
      -----------------------------  -----------------------------  --------- 
                                      10.31 pence per share         100,000 
    10.46 pence per share                                             50,000 
  ----------------------------------------------------------------  --------- 
 d     Aggregated information 
        - Aggregated volume                   *    150,000 
        - Price 
 
                                              *    10.36p 
      -----------------------------  ---------------------------------------- 
 e)    Date of the transactions       19 January 2022 
      -----------------------------  ---------------------------------------- 
 f)    Place of the transactions      London Stock Exchange (XLON); Main 
                                       Market 
      -----------------------------  ----------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBDGDBUUBDGDC

(END) Dow Jones Newswires

January 19, 2022 07:56 ET (12:56 GMT)

Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024